Tonix director buys 1,415 shares in open market

Tonix Pharmaceuticals Holding Corp. director Carolyn E. Taylor reported an open-market purchase of common stock.

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. director Carolyn E. Taylor reported an open-market purchase of common stock. She bought 1,415 shares of Tonix common stock at an average price of $10.55 per share. After this transaction, she directly owns 1,833 shares of Tonix common stock.

Insider Trade Summary

Net Buyer: 1,415 shares

Net Buy 1 txn

Insider Taylor Carolyn E.

Role Director

Bought 1,415 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $0.001 par value	1,415	$10.55	$15K

Holdings After Transaction: Common Stock, $0.001 par value — 1,833 shares (Direct)

Key Figures

Shares purchased: 1,415 shares Purchase price: $10.55 per share Shares owned after: 1,833 shares +1 more

4 metrics

Shares purchased 1,415 shares Open-market buy on 2026-06-12

Purchase price $10.55 per share Common Stock, $0.001 par value

Shares owned after 1,833 shares Direct ownership following transaction

Net buy shares 1,415 shares Net-buy direction in this Form 4

Key Terms

Form 4, open-market purchase, direct ownership, Common Stock, $0.001 par value

4 terms

Form 4 regulatory

"according to a Form 4 insider trading report filed for this transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market purchase financial

"reported an open-market purchase of 1,415 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

direct ownership financial

"Following the reported transaction, Carolyn E. Taylor directly owns 1,833 shares"

Common Stock, $0.001 par value financial

"Common Stock, $0.001 par value"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tonix Pharmaceuticals (TNXP) report for Carolyn E. Taylor?

Tonix director Carolyn E. Taylor reported an open-market purchase of 1,415 shares of common stock. The shares were bought at an average price of $10.55 each, increasing her directly held position in Tonix Pharmaceuticals to 1,833 shares.

How many Tonix Pharmaceuticals (TNXP) shares did Carolyn E. Taylor buy and at what price?

Carolyn E. Taylor purchased 1,415 Tonix common shares in an open-market transaction. The reported average purchase price was $10.55 per share, as disclosed in the Form 4 insider trading report filed for this transaction.

What is Carolyn E. Taylor’s total Tonix Pharmaceuticals (TNXP) ownership after this Form 4?

Following the reported transaction, Carolyn E. Taylor directly owns 1,833 shares of Tonix common stock. This figure reflects her holdings after buying 1,415 shares in the open market at an average price of $10.55 per share.

Was the Tonix Pharmaceuticals (TNXP) insider transaction a buy or a sell?

The insider transaction was a buy. Director Carolyn E. Taylor executed an open-market purchase of 1,415 Tonix common shares at an average price of $10.55, increasing her directly held ownership to a total of 1,833 shares.

Is the Tonix Pharmaceuticals (TNXP) insider trade by Carolyn E. Taylor direct ownership?

Yes, the filing classifies the position as direct ownership. After purchasing 1,415 Tonix common shares at $10.55 each in the open market, Carolyn E. Taylor directly holds a total of 1,833 Tonix Pharmaceuticals shares under ownership code "D".

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 07:00 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Carolyn E.

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.001 par value	06/12/2026		P		1,415	A	$10.55	1,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jessica Morris as attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)